Comparison of variables for correlations, and as covariates for the survival curves, in 67 children with JIA-associated uveitis and in 27 with IdCU. Continuous variables are expressed as median (range) values.
| Variable | JIA Uveitis, n = 67 | IdCU, n = 27 | p |
|---|---|---|---|
| Age, yrs | 10.8 (3.2–12.3) | 13.4 (5.2–15.4) | 0.13 |
| Female/male, n | 49/18 | 11/16 | 0.82 |
| Age at onset of uveitis, yrs | 5.4 (2.2–11.4) | 7.2 (4.6–11.2) | 0.09 |
| Uveitis history duration, mos | 31 (12–68) | 28 (11–84) | 0.73 |
| Time interval between uveitis onset and systemic treatment able to achieve remission, mos | 48 (6–75) | 40 (12–84) | 0.71 |
| Systemic treatment duration, mos | 25 (8–51) | 20 (9–46) | 0.32 |
| MTX, n (%) | 41 (61.2) | 12 (44.5) | 0.21 |
| Infliximab, n (%) | 3 (4.5) | 2 (7.4) | 0.94 |
| Adalimumab, n (%) | 23 (34.3) | 13 (48.1) | 0.31 |
| Concomitant MTX administration, n/no. receiving anti-TNF-α | 18/26 | 10/15 | 0.6 |
| Time of remission, mos | 11 (6–28) | 13.1 (6–59) | 0.0001 |
| Total time followup, mos | 48 (26–68) | 50 (15–65) | 0.91 |
| No. previous flares before systemic treatment | 4 (2–6) | 3 (2–7) | 0.43 |
| BCVA as LogMAR, at the study entry, mean (± SD) | 0.24 (0.36) | 0.23 (0.32) | 0.6 |
| Patients with eye complications due to chronic uveitis, n (%) | 11 (16.6) | 4 (14.8) | 0.84 |
Significant data are in bold face. JIA: juvenile idiopathic arthritis; IdCU: idiopathic chronic uveitis; BCVA: best corrected visual acuity; MTX: methotrexate; anti-TNF-α: antitumor necrosis factor-α.